Technology Enhanced Nurse Navigator Trial (TENN Trial) (TENN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01596179
Recruitment Status : Completed
First Posted : May 10, 2012
Last Update Posted : April 17, 2015
Susan G. Komen Breast Cancer Foundation
Maryland Department of Health and Mental Hygiene
Information provided by (Responsible Party):
Mercy Medical Center

Brief Summary:
The purpose of the Technology Enhanced Nurse Navigator Trial (TENN) Trial is to find the best way to provide breast cancer patients with information through a computer connected to the internet. The study will determine if giving information during treatment may help patients cope better with their treatment. The hypothesis is that participants assigned to receive Technology-Enhanced Nurse-directed Navigation will be more likely to adhere to treatment regimens and have improved symptom management than women who have access to the education portal only.

Condition or disease Intervention/treatment Phase
Medication Adherence Behavioral: Interactive navigational support Behavioral: Internet access Phase 3

Detailed Description:
Treatment for breast cancer has been proven to decrease death from breast cancer. The key to the success of treatment is getting the right dose at the right time, but many women do not receive optimum treatment. Treatment delays, missed appointments, and failure to take medication on a regular basis lead to poorer survival from breast cancer. In a study among low income women only 60% of women adhered to the treatment, that is, taking their medication at least 80% of the time. Twenty percent of women, who were supposed to take 5 years of hormone treatment, had stopped their medication in the first year. Similar problems occur with chemotherapy and radiation therapy. Many barriers interfere with adherence to treatment, including poor symptom management, missed appointments, and cancelled appointments. Nurse navigation can help manage and minimize symptoms, assist with appointment reminders, and answer questions to obtain optimum breast cancer treatment. The goal of the proposed study is to rigorously test the delivery of nurse-navigation through a web-based knowledge and communication portal (Technology Enhanced Nurse-directed Navigation (TENN) for its impact on treatment adherence and symptom management. The success of this program will be measured by improved treatment adherence, health outcome measures such as fatigue and symptom management, patient-reported quality of life, reduced distress, and patient satisfaction.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 101 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: Technology Enhanced Nurse Navigator Trial (TENN Trial) Phase III Randomized Controlled Trial
Study Start Date : February 2012
Actual Primary Completion Date : February 2015
Actual Study Completion Date : February 2015

Arm Intervention/treatment
Experimental: Interactive navigational support
Patients on the intervention arm are provided with a netbook computer and internet access with ongoing interaction with a nurse and a social worker navigators for a one year period.
Behavioral: Interactive navigational support
Interactive navigational support is provided by a nurse and social worker navigators

Active Comparator: control arm
Patients on the control arm are provided with a netbook computer, internet access and general website information but no interactive navigational support for a one year period.
Behavioral: Internet access
a netbook computer with internet access is provided to participants on the control arm.

Primary Outcome Measures :
  1. Treatment Adherence [ Time Frame: Baseline, 6 months and 12 months ]
    Adherence will be determined by review of the claims data. All claims, including hormone, chemotherapy and radiation therapy, doctor's visits, and hospitalizations, are sent through the BCCDT program. For chemotherapy and radiation therapy, relative dose intensity (RDI) will be measured. Adherence to hormone therapy will be measured as the medication possession ratio (MPR).A self-reported measure of adherence will be correlated with these more objective measures (Morisky et al. 1986).

  2. Fatigue [ Time Frame: Baseline, 6 months and 12 months ]
    Fatigue will be measured using a visual analogue scale. The FACT-B will be used to measure quality of life. The FACT-B is the Functional Assessment of Cancer Therapy-Breast, a reliable and valid measure for assessing subjective health-related quality of life among breast cancer survivors (Brady et al. 1997). The FACT-B includes both the FACT-General (FACT-G) and the Breast Cancer Subscale (BCS). The FACT-B has shown high internal consistency with a Cronbach's alpha of 0.90 (Brady et al. 1997).

Secondary Outcome Measures :
  1. Patient satisfaction [ Time Frame: Baseline, 6 months and 12 months ]
    As recommended by the NCI Navigation Research Program, we will include the Communication and Attitudinal Self-Efficacy scale for cancer (CASE-cancer) designed to measure self-efficacy and positive attitude for cancer patients (Wolf et al. 2005).

  2. Quality of life [ Time Frame: Baseline, 6 months and 12 months ]
    As a measure of distress, we will use the Impact of Events scale revised (IES-R), an updated version of the original Impact of Events scale (IES) (Horowitz et al. 1979;Weiss et al. 1997). The IES-R is a validated measure of responses to a stressful life event and addresses distress and intrusive thoughts consistent with responses to the DSM-IV diagnosis criteria of PTSD. The IES-R is readily modified to address an event such as diagnosis of cancer or a chemotherapy-related adverse event

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Enrolled in the BCCDT program for the adjuvant treatment of breast cancer,currently on medical assistance,or with an income that does not exceed 300% of the Federal Poverty Level, based on family size.
  • English-speaking
  • Able to give informed consent
  • Not enrolled in another case-management program
  • Residing within the Verizon 3G Coverage area

Exclusion Criteria:

  • Non-English speaking
  • Enrolled in a case management program.
  • Unable to sign an informed consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01596179

United States, Maryland
The Prevention and Research Center at Mercy Medical Center
Baltimore, Maryland, United States, 21202
Sponsors and Collaborators
Mercy Medical Center
Susan G. Komen Breast Cancer Foundation
Maryland Department of Health and Mental Hygiene
Principal Investigator: Kathy Helzlsouer, M.D., M.H.S. The Prevention and Research Center at Mercy Medical Center

Responsible Party: Mercy Medical Center Identifier: NCT01596179     History of Changes
Other Study ID Numbers: MMC2011-001
First Posted: May 10, 2012    Key Record Dates
Last Update Posted: April 17, 2015
Last Verified: January 2015

Keywords provided by Mercy Medical Center:
treatment adherence
symptom management